Lung Cancer Management最新文献

{"title":"Genomic epidemiology reveals the impact of national and international restrictions measures on the SARS-CoV-2 epidemic in Brazil.","authors":"Marta Giovanetti, Svetoslav Nanev Slavov, Vagner Fonseca, Eduan Wilkinson, Houriiyah Tegally, José Salvatore Leister Patané, Vincent Louis Viala, James Emmanuel San, Evandra Strazza Rodrigues, Elaine Vieira Santos, Flavia Aburjaile, Joilson Xavier, Hegger Fritsch, Talita Emile Ribeiro Adelino, Felicidade Pereira, Arabela Leal, Felipe Campos de Melo Iani, Glauco de Carvalho Pereira, Cynthia Vazquez, Gladys Mercedes Estigarribia Sanabria, Elaine Cristina de Oliveira, Luiz Demarchi, Julio Croda, Rafael Dos Santos Bezerra, Loyze Paola Oliveira de Lima, Antonio Jorge Martins, Claudia Renata Dos Santos Barros, Elaine Cristina Marqueze, Jardelina de Souza Todao Bernardino, Debora Botequio Moretti, Ricardo Augusto Brassaloti, Raquel de Lello Rocha Campos Cassano, Pilar Drummond Sampaio Corrêa Mariani, João Paulo Kitajima, Bibiana Santos, Rodrigo Proto-Siqueira, Vlademir Vicente Cantarelli, Stephane Tosta, Vanessa Brandão Nardy, Luciana Reboredo de Oliveira da Silva, Marcela Kelly Astete Gómez, Jaqueline Gomes Lima, Adriana Aparecida Ribeiro, Natália Rocha Guimarães, Luiz Takao Watanabe, Luana Barbosa Da Silva, Raquel da Silva Ferreira, Mara Patricia F da Penha, María José Ortega, Andrea Gómez de la Fuente, Shirley Villalba, Juan Torales, María Liz Gamarra, Carolina Aquino, Gloria Patricia Martínez Figueredo, Wellington Santos Fava, Ana Rita C Motta-Castro, James Venturini, Sandra Maria do Vale Leone de Oliveira, Crhistinne Cavalheiro Maymone Gonçalves, Maria do Carmo Debur Rossa, Guilherme Nardi Becker, Mayra Marinho Presibella, Nelson Quallio Marques, Irina Nastassja Riediger, Sonia Raboni, Gabriela Mattoso Coelho, Allan Henrique Depieri Cataneo, Camila Zanluca, Claudia N Duarte Dos Santos, Patricia Akemi Assato, Felipe Allan da Silva da Costa, Mirele Daiana Poleti, Jessika Cristina Chagas Lesbon, Elisangela Chicaroni Mattos, Cecilia Artico Banho, Lívia Sacchetto, Marília Mazzi Moraes, Rejane Maria Tommasini Grotto, Jayme A Souza-Neto, Maurício Lacerda Nogueira, Heidge Fukumasu, Luiz Lehmann Coutinho, Rodrigo Tocantins Calado, Raul Machado Neto, Ana Maria Bispo de Filippis, Rivaldo Venancio da Cunha, Carla Freitas, Cassio Roberto Leonel Peterka, Cássia de Fátima Rangel Fernandes, Wildo Navegantes de Araújo, Rodrigo Fabiano do Carmo Said, Maria Almiron, Carlos Frederico Campelo de Albuquerque E Melo, José Lourenço, Tulio de Oliveira, Edward C Holmes, Ricardo Haddad, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Simone Kashima, Luiz Carlos Junior de Alcantara, Dimas Tadeu Covas","doi":"10.1101/2021.10.07.21264644","DOIUrl":"10.1101/2021.10.07.21264644","url":null,"abstract":"<p><p>Brazil has experienced some of the highest numbers of COVID-19 cases and deaths globally and from May 2021 made Latin America a pandemic epicenter. Although SARS-CoV-2 established sustained transmission in Brazil early in the pandemic, important gaps remain in our understanding of virus transmission dynamics at the national scale. Here, we describe the genomic epidemiology of SARS-CoV-2 using near-full genomes sampled from 27 Brazilian states and a bordering country - Paraguay. We show that the early stage of the pandemic in Brazil was characterised by the co-circulation of multiple viral lineages, linked to multiple importations predominantly from Europe, and subsequently characterized by large local transmission clusters. As the epidemic progressed under an absence of effective restriction measures, there was a local emergence and onward international spread of Variants of Concern (VOC) and Variants Under Monitoring (VUM), including Gamma (P.1) and Zeta (P.2). In addition, we provide a preliminary genomic overview of the epidemic in Paraguay, showing evidence of importation from Brazil. These data reinforce the usefulness and need for the implementation of widespread genomic surveillance in South America as a toolkit for pandemic monitoring that provides a means to follow the real-time spread of emerging SARS-CoV-2 variants with possible implications for public health and immunization strategies.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90208758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC","authors":"A. Kulkarni, N. Fujioka, Lucia Reinhardt, Manish R. Patel, R. Kratzke","doi":"10.2217/lmt-2021-0001","DOIUrl":"https://doi.org/10.2217/lmt-2021-0001","url":null,"abstract":"We present a patient with metastatic NSCLC harboring a compound EGFR mutation with co-occurring G719A and T790M mutation. T790M mutation was treatment emergent mutation when patient was on early generation tyrosine kinase inhibitors. Initial Guardant 360 showed that G719A was the dominant clone. Following, osimertinib, the patient had only a radiographic disease stabilization and then developed both clinical and radiographic progression. On progression, T790M was undetectable but G719A continued to be the dominant clone. Subsequent administration of afatinib led to a clinical and radiological response. To our knowledge, this is the first case report describing co-occurrence of EGFR G719A and T790M mutations and the clonal evolution during treatment with anti-EGFR therapies.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42910291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study.","authors":"Belen Rubio-Viqueira,&nbsp;Margarita Majem Tarruella,&nbsp;Martín Lázaro,&nbsp;Sergio Vázquez Estévez,&nbsp;Juan Felipe Córdoba-Ortega,&nbsp;Inmaculada Maestu Maiques,&nbsp;Jorge García González,&nbsp;Ana Blasco Cordellat,&nbsp;Javier Valdivia-Bautista,&nbsp;Carmen González Arenas,&nbsp;Jose Miguel Sánchez Torres","doi":"10.2217/lmt-2021-0008","DOIUrl":"https://doi.org/10.2217/lmt-2021-0008","url":null,"abstract":"<p><strong>Aim: </strong>To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain.</p><p><strong>Methods: </strong>Multicenter, retrospective study.</p><p><strong>Results: </strong>Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1.</p><p><strong>Conclusion: </strong>PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 4","pages":"LMT53"},"PeriodicalIF":2.8,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/81/lmt-10-53.PMC8656292.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39720172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enabling patients in effective self-management of breathlessness in lung cancer: the neglected pillar of personalized medicine.","authors":"Doris Howell","doi":"10.2217/lmt-2020-0017","DOIUrl":"10.2217/lmt-2020-0017","url":null,"abstract":"<p><p>Globally, engagement of patients in the self management of disease and symptom problems has become a health policy priority to improve health outcomes in cancer. Unfortunately, little attention has been focused on the provision of self-management support (SMS)in cancer and specifically for complex cancer symptoms such as breathlessness. Current management of breathlessness, which includes treatment of underlying disease, pharmacological agents to address comorbidities and opiates and anxiolytics to change perception and reduce the sense of breathing effort, is inadequate. In this perspective paper, we review the rationale and evidence for a structured, multicomponent SMS program in breathlessness including four components: breathing retraining, enhancing positive coping skills, optimizing exertional capacity and reducing symptom burden and health risks. The integration of SMS in routine lung cancer care is essential to improve breathlessness, reduce psychological distress, suffering and improve quality of life.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 4","pages":"LMT52"},"PeriodicalIF":2.8,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/2d/lmt-10-52.PMC8656340.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39720171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data.","authors":"Virginia Calvo,&nbsp;Marta Andrés Fernández,&nbsp;Ana Collazo-Lorduy,&nbsp;Fernando Franco,&nbsp;Beatriz Núñez,&nbsp;Mariano Provencio","doi":"10.2217/lmt-2021-0003","DOIUrl":"https://doi.org/10.2217/lmt-2021-0003","url":null,"abstract":"<p><strong>Aim: </strong>Immune checkpoint inhibitors (ICIs) are a cornerstone in cancer treatment but they can induce immune-related adverse events (irAEs). Furthermore, patients with pre-existing autoimmune and/or inflammatory disease (AID) have been excluded from clinical trials. The objective of this study is to evaluate the efficacy and safety of ICIs in patients with cancer and AID.</p><p><strong>Materials & methods: </strong>This is an observational, retrospective study carried out at the Medical Oncology Department of Hospital Universitario Puerta de Hierro, Majadahonda, Madrid between January 2016 and December 2018.</p><p><strong>Results: </strong>A total of 202 cancer patients treated with ICIs were included, 15 (7, 4%) of them had pre-existing autoimmune diseases. The most frequent pre-existing AID were thyroid diseases (33.3%): autoimmune hypothyroidism, Graves-Basedow disease and Hashimoto's thyroiditis. Three patients had psoriasis, two antinuclear antiboides + polyarthritis, one rheumatoid arthritis, another latent autoimmune diabetes in adults, another systemic lupus erythematosus and the last one, a polymyalgia rheumatica. In this series, the majority of patients (73.33%) did not experience any flare up of their autoimmune disease. In patients who had AID flare up, this was treated with corticosteroids. The most frequent cause of immunotherapy discontinuation was tumor progression (40%). A total of 20% of patients had to discontinue immunotherapy due to toxicity.</p><p><strong>Conclusion: </strong>In our series, AID flare ups or irAEs in patients with pre-existing AID who receive immunotherapy are not very common and can often be controlled without interrupting treatment. Prospective studies are needed to establish the incidence of irAEs in patients with pre-existing autoimmune conditions, evaluate risk-benefit and elaborate management clinical guidelines in this population.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 4","pages":"LMT51"},"PeriodicalIF":2.8,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/a3/lmt-10-51.PMC8656306.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39720169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphadenopathy and granulomas: benignancy of malignancy and differential diagnosis with endobronchial ultrasound-transbronchial needle biopsy 19G needle fine-needle aspiration biopsy.","authors":"Paul Zarogoulidis,&nbsp;Dimitris Hatzibougias,&nbsp;Kosmas Tsakiridis,&nbsp;Dimitris Matthaios,&nbsp;Wolfgang Hohenforst-Schmidt,&nbsp;Haidong Huang,&nbsp;Chong Bai,&nbsp;Stavros Tryfon,&nbsp;Maria Saroglou,&nbsp;Bojan Zaric,&nbsp;Ioannis Boujkovinas,&nbsp;Chrisanthi Karapantzou","doi":"10.2217/lmt-2021-0002","DOIUrl":"https://doi.org/10.2217/lmt-2021-0002","url":null,"abstract":"<p><p>Endobronchial ultrasound (EBUS) is a very useful tool for the diagnosis of lymphadenopathy of the mediastinum. Nowadays, EBUS can substitute video-assisted thoracic surgery when a 19G needle is used. Several studies have provided data for efficient diagnosis not only for lung cancer, but for also sarcoidosis, tuberculosis and lymphoma. We present five cases of EBUS-transbronchial needle biopsy 19G needle used for the diagnosis of mediastinum lymphadenopathy. We present not only the pathological diagnosis, but also the steps for the differential clinical and pathological differential diagnosis for sarcoidosis, tuberculosis, cancer metastasis, respiratory infection and lymphoma.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 3","pages":"LMT49"},"PeriodicalIF":2.8,"publicationDate":"2021-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/84/lmt-10-49.PMC8369527.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in lung cancer screening rates among the Hispanic/LatinX population.","authors":"Coral Olazagasti,&nbsp;Nagashree Seetharamu","doi":"10.2217/lmt-2021-0004","DOIUrl":"https://doi.org/10.2217/lmt-2021-0004","url":null,"abstract":"“Ultimately, the newly proposed lung cancer screening guidelines serve as hope for high-risk subjects of Hispanic/LatinX ethnicity whom, until now, have often missed out on opportunities to undergo lung cancer screening. With these new broader lung cancer screening guidelines, eligibility for high-risk Hispanic/LatinX individuals should increase, therefore improving their rates of earlier detection and overall lung cancer mortality.”","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 3","pages":"LMT51"},"PeriodicalIF":2.8,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/94/lmt-10-51.PMC8369520.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER3 expression and MEK activation in non-small-cell lung carcinoma.","authors":"Thubeena Manickavasagar,&nbsp;Wei Yuan,&nbsp;Suzanne Carreira,&nbsp;Bora Gurel,&nbsp;Susana Miranda,&nbsp;Ana Ferreira,&nbsp;Mateus Crespo,&nbsp;Ruth Riisnaes,&nbsp;Chloe Baker,&nbsp;Mary O'Brien,&nbsp;Jaishree Bhosle,&nbsp;Sanjay Popat,&nbsp;Udai Banerji,&nbsp;Juanita Lopez,&nbsp;Johann de Bono,&nbsp;Anna Minchom","doi":"10.2217/lmt-2020-0031","DOIUrl":"https://doi.org/10.2217/lmt-2020-0031","url":null,"abstract":"<p><strong>Aim: </strong>We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression.</p><p><strong>Materials & methods: </strong>Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 expression were identified using immunohistochemistry and bioinformatic interrogation of The Cancer Genome Atlas (TCGA).</p><p><strong>Results: </strong>HER3 was highly expressed in 42.2% of cases. <i>ERBB3</i> copy number did not account for HER3 overexpression. Bioinformatic analysis of TCGA demonstrated that MEK activity score (a surrogate of functional signaling) did not correlate with HER3 ligands. <i>ERBB3</i> RNA expression levels were significantly correlated with MEK activity after adjusting for <i>EGFR</i> expression.</p><p><strong>Conclusion: </strong>HER3 expression is common and is a potential therapeutic target by virtue of frequent overexpression and functional downstream signaling.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 2","pages":"LMT48"},"PeriodicalIF":2.8,"publicationDate":"2021-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/37/lmt-10-48.PMC8162178.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39059396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma.","authors":"Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Manuel Martínez-Barrera, Carla Paola Sánchez-Ríos, Adriana Martinez-Camacho, José Fabián Martínez-Herrera, Jordi Guzmán-Casta, Rodrigo Rafael Flores-Mariñelarena, Julián Diaz-Rico, Patricio Santillán-Doherty","doi":"10.2217/lmt-2020-0027","DOIUrl":"10.2217/lmt-2020-0027","url":null,"abstract":"<p><strong>Background: </strong>Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy.</p><p><strong>Materials & methods: </strong>This was a retrospective review among eight medical centers comprising 100 patients with a confirmed diagnosis of non-small-cell lung carcinoma, in their second-line treatment or beyond with immune checkpoints inhibitors treatment. The current study aimed to analyze effectiveness of immunotherapy in second-line treatment or further in the Mexican population, using PFS rate, OS rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness.</p><p><strong>Results: </strong>In total, 100 patients met the criteria for enrollment in the current study. From the total study population, 49 patients (49.0%) were male and 51 (51.0%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the study. A total of 61 patients (61.0%) had partial response; 11 (11.0%) stable disease; 2 (2.0%), complete response, 4 (4.0%), progression; and 22 (22.0%) were nonevaluable. We found a median PFS of 4 months (95% CI: 3.2-4.7 months) and an OS of 9 months (95% CI: 7.2-10.7 months).</p><p><strong>Conclusion: </strong>The response to immunotherapy is similar, with an improvement in OS and PFS, independent of which drug is used. Patients using nivolumab had a better survival, although that was not statistically significant.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 3","pages":"LMT47"},"PeriodicalIF":0.9,"publicationDate":"2021-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/6a/lmt-10-47.PMC8369526.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database.","authors":"Marta Soares,&nbsp;Luís Antunes,&nbsp;Patrícia Redondo,&nbsp;Marina Borges,&nbsp;Ruben Hermans,&nbsp;Dony Patel,&nbsp;Fiona Grimson,&nbsp;Robin Munro,&nbsp;Carlos Chaib,&nbsp;Laure Lacoin,&nbsp;Melinda Daumont,&nbsp;John R Penrod,&nbsp;John C O'Donnell,&nbsp;Maria José Bento,&nbsp;Francisco Rocha Gonçalves","doi":"10.2217/lmt-2020-0028","DOIUrl":"https://doi.org/10.2217/lmt-2020-0028","url":null,"abstract":"<p><strong>Aim: </strong>This observational study evaluated treatment patterns and survival for patients with stage I-IIIA non-small-cell lung cancer (NSCLC).</p><p><strong>Materials & methods: </strong>Adults newly diagnosed with NSCLC in 2012-2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015-2016.</p><p><strong>Results: </strong>495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012-2016) were 92% (88-96), 71% (62-82) and 69% (63-75), respectively; one-year OS (95% CI) for treated patients with stage I-II or stage IIIA NSCLC (diagnosed 2015-2016) were 89% (81-97) and 86% (75-98) for non-squamous cell and 76% (60-95) and 49% (34-70) for squamous cell NSCLC.</p><p><strong>Conclusion: </strong>Treatment advances are strongly needed for stage I-IIIA NSCLC, especially for patients with squamous cell histology.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 2","pages":"LMT46"},"PeriodicalIF":2.8,"publicationDate":"2021-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/f5/lmt-10-46.PMC8162184.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39059395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}